Dawnrays Pharmaceutical (Holdings) Ltd. ( China (Mainland))

Dawnrays Pharmaceutical (Holdings) Ltd. is a listed company in Hong Kong Stock Exchange Market which is specialized in the development, manufacturing and the sale of cephalosporin antibiotics, and various system specific (generic) medicines such as L(+)-Arginine with cas registry number of 74-79-3, Cefazolin Sodium salt with cas registry number of 27164-46-1, Cefoxitin sodium with cas registry number of 33564-30-6, Cefoxitin with cas registry number of 35607-66-0, Methyl isobutyrylacetate with cas registry number of 42558-54-3. The product range covers bulk medicine, powder for injection, tablets, capsules, granules and midbody.

To ensure the quality, Dawnrays is equipped with advanced production process and techniques, especially advanced technology of solvent crystallization. The quality has met to the international standard. Cefoperazone Sodium bulk medicine and its powder for injection form by solvent crystallization has been recognized as the "High and New Technology Products of Jiangsu Province" and has been dominating a big market share in China.

Dawnrays is founded on 8th December 1995 by a Hong Kong investor. Now it has four subsidiaries incliding Suzhou Dawnrays Pharmaceuticals Co., Ltd., Suzhou Dawnrays Chemical Co., Ltd., Shanghai Dawnrays Chemical Co., Ltd. and Dawnrays Pharma (Hong Kong) Ltd.. Dawnrays has its own brands. Amlodipine Besylate Tablets is brand named "AnNeiZhen" and Cetirizine Hydrochloride Tablets is brand named "XiKeWei". These  brand names has becom famous.

Dawnrays will continue to produce low-cost high quality medicines in the market and achieve to become one of the best pharmaceutical companies in China.